CA2577288C - Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile - Google Patents

Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile Download PDF

Info

Publication number
CA2577288C
CA2577288C CA2577288A CA2577288A CA2577288C CA 2577288 C CA2577288 C CA 2577288C CA 2577288 A CA2577288 A CA 2577288A CA 2577288 A CA2577288 A CA 2577288A CA 2577288 C CA2577288 C CA 2577288C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
compound
composition according
formula
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2577288A
Other languages
English (en)
Other versions
CA2577288A1 (fr
Inventor
Paul Theodoor Agnes Stevens
Jozef Peeters
Roger Petrus Gerebern Vandecruys
Alfred Elisabeth Stappers
Alex Herman Copmans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34940340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2577288(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from MYPI20043578A external-priority patent/MY169670A/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2577288A1 publication Critical patent/CA2577288A1/fr
Application granted granted Critical
Publication of CA2577288C publication Critical patent/CA2577288C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant, en tant que principe actif, le sel d'acide chlorhydrique de 4-[[4-[[4-(2-cyanoéthényl)-2,6-diméthyl-phényl]amino]-2-pyrimidinyl]amino] benzonitrile ainsi que des procédés de préparation de ladite composition.
CA2577288A 2004-09-02 2005-09-02 Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile Expired - Lifetime CA2577288C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
MYPI20043578 2004-09-02
MYPI20043578A MY169670A (en) 2003-09-03 2004-09-02 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (fr) 2003-09-03 2004-09-03 Combinaisons d'une pyrimidine renfermant nnrti avec des inhibiteurs de rt
EPPCT/EP2004/052028 2004-09-03
EP05101467.8 2005-02-25
EP05101467 2005-02-25
PCT/EP2005/054342 WO2006024668A1 (fr) 2004-09-02 2005-09-02 Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number Publication Date
CA2577288A1 CA2577288A1 (fr) 2006-03-09
CA2577288C true CA2577288C (fr) 2010-11-30

Family

ID=34940340

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2577288A Expired - Lifetime CA2577288C (fr) 2004-09-02 2005-09-02 Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Country Status (3)

Country Link
AU (1) AU2005279158C1 (fr)
CA (1) CA2577288C (fr)
WO (1) WO2006024668A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
PT1981506E (pt) * 2006-01-20 2013-06-25 Janssen R & D Ireland Tratamento a longo prazo da infeção pelo vih com tmc278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
PL2155169T3 (pl) * 2007-06-08 2016-09-30 Formulacja newirapiny o przedłużonym uwalnianiu
CA2693044C (fr) * 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Forme cristalline de of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
WO2012125993A1 (fr) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Formes à l'état solide de base rilpivirine et sels de rilpivirine
EP2755959B1 (fr) * 2011-09-16 2018-05-16 Hetero Research Foundation Chlorhydrate de rilpivirine
EP2604593A1 (fr) * 2011-12-14 2013-06-19 Sandoz AG Polymorphe du chlorhydrate de rilpivirine et son utilisation comme antiviral
WO2013087794A1 (fr) * 2011-12-14 2013-06-20 Sandoz Ag Polymorphe de chlorhydrate de rilpivirine et son utilisation à titre d'antiviral
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
DK1529032T3 (da) * 2002-08-09 2013-07-08 Janssen Pharmaceutica Nv Fremgangsmåder til fremstilling af 4-4-4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)aminobenzonitrill

Also Published As

Publication number Publication date
WO2006024668A1 (fr) 2006-03-09
CA2577288A1 (fr) 2006-03-09
AU2005279158A1 (en) 2006-03-09
AU2005279158C1 (en) 2010-12-16
AU2005279158B2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
US7956063B2 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
IL181650A (en) Solid pharmaceutical composition comprising a pharmaceutically acceptable carrier and hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile and use thereof in the manufacture of a medicament for treating or preventing hiv infection
CA2577288C (fr) Chlorhydrate de 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US8101629B2 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
CA3039562A1 (fr) Compositions dispersibles
US20180116964A1 (en) Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2006024667A1 (fr) Furamate de 4- ( (4- ( (4- (2-cyanoethenyl) -2, 6-dimethylphenyl) amino) -2-pyrimidinyl) amino) benzonitrile
NZ553323A (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, also named TMC278
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
NZ553322A (en) Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also named TMC278
HK1112862B (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile

Legal Events

Date Code Title Description
EEER Examination request